Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions

Breast Cancer

Interventions

DRUG

Adebrelimab

adebrelimab:1200mg intravenously, Q3W.

DRUG

dalpiciclib

dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.

Trial Locations (1)

RECRUITING

Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Tongji Hospital

OTHER